Early Renal Function Decline in Type 2 Diabetes

Centers for Disease Control and Prevention, 4770 Buford Hwy, NE MS-K10, Atlanta, GA 30341-3724, USA.
Clinical Journal of the American Society of Nephrology (Impact Factor: 5.25). 11/2011; 7(1):78-84. DOI: 10.2215/CJN.07610711
Source: PubMed

ABSTRACT Early decline in GFR may reflect progressive kidney disease in type 1 diabetes, but its predictive value in type 2 diabetes is uncertain.
In this longitudinal study, GFR was measured serially over approximately 4.0 years in 195 Pima Indians with type 2 diabetes. Renal function decline (RFD) was defined during this initial period by an average GFR loss ≥3.3%/yr, as defined previously in type 1 diabetes. Subsequently, participants were followed for up to 17.8 years to ESRD onset, death, or December 31, 2010, whichever came first.
RFD prevalence during the initial period was 32% in 68 participants with normal baseline albuminuria (albumin/creatinine ratio [ACR] < 30 mg/g), 42% in 88 with microalbuminuria (ACR 30 to <300 mg/g), and 74% in 39 with macroalbuminuria (ACR ≥300 mg/g; P<0.001). The cumulative incidence of ESRD 10 years after the initial period was 41% in those with RFD and 15% in those without (P<0.001); 41 of the 49 ESRD cases (83.7%) occurred in participants who had or developed macroalbuminuria during the initial period. When adjusted for age, sex, diabetes duration, and hemoglobin A1c, the ESRD hazard rate was 4.78 times (95% confidence interval, 2.39-9.58) as high in those with RFD as in those without; further adjustment for albuminuria attenuated this association (hazard ratio, 1.79; 95% confidence interval, 0.82-3.91).
In type 2 diabetes, loss of GFR often occurs before the onset of macroalbuminuria, but a decline predictive of ESRD is strongly dependent on progression to macroalbuminuria.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depending on age, duration of diabetes and glycaemic control, 20–40% of patients with type 2 diabetes will incur a moderate or severe deterioration of renal function. This will impact the choice of blood glucose-lowering therapy and require more frequent monitoring of both renal function and glycaemic control. Moderate renal impairment (glomerular filtration rate 30 – < 60 ml/min) requires consideration of dose reduction or treatment cessation for metformin, glucagon-like peptide-1 receptor agonists, some sulphonylureas and some dipeptidyl peptidase-4 inhibitors. At lower rates of glomerular filtration down to about 15 ml/min it may be appropriate to use a meglitinide, pioglitazone or certain sulphonylureas with careful consideration of dose and co-morbidities. Dipeptidyl peptidase-4 inhibitors can be used at reduced dose in patients with very low rates of glomerular filtration, and linagliptin can be used without dose reduction, and has been used in patients on dialysis. Insulin can be used at any stage of renal impairment, but the regimen and the dose must be suitably adjusted and accompanied by adequate monitoring.
    The British Journal of Diabetes & Vascular Disease 09/2012; 12(4):167-171. DOI:10.1177/1474651412458811
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents a built-in self test pump actuated by piezoelectric bimorphs for fluidic systems. The sensor fabricated by MEMS ensures the flow to be 0.1 mul/s. The pump is characterized by thin structure, precise rate of flow, low power consumption, etc. A prototype of the pump, with a size of 20 mm, 20 mm and 7 mm, is fabricated by precise manufacturing. Simulations and experiments show that the piezoelectric pump has high efficiency and good performance. With a voltage of 75 V, the flow rate is 0.5 mul every three electronic pulses and its power consumption is only 2.6 mW. A robust passive high pressure check valve is developed for piezoelectric actuated pumps. A novel metal check valve flap is used to increase the valve's structural stiffness with pressures up to 20.4 kPa. A series-wound multi-pump chamber structure prevents valve-flap from failure under extreme high pressure.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Surrogate end points of renal failure are instrumental to the testing of new treatments in patients with chronic kidney disease, the natural history of which is characterized by a slow, asymptomatic decline in renal function. The magnitude of proteinuria is widely recognized as a marker of the severity of glomerulopathy. Population-based studies have identified proteinuria as a predictor of future decline in glomerular filtration rate and of the development of end-stage renal disease. More importantly, a reduction in proteinuria invariably translates into a protection from renal function decline in patients with diabetic and nondiabetic renal disease with overt proteinuria. Thus, proteinuria should be considered a valuable surrogate end point for clinical trials in patients with proteinuric renal diseases.
    Nature Reviews Nephrology 03/2012; 8(5):301-6. DOI:10.1038/nrneph.2012.42 · 8.37 Impact Factor